Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit – if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. The pace and demand are picking up in the United States. In other countries, including some where the research took place, there is limited or no access. For maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research, and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills, or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

A mathematical model developed by two researchers at Imperial College in London, and based on what would happen if PrEP was introduced to a high-prevalence region in Kenya, shows that PrEP could be a ‘runaway success’ or a ‘runaway failure’, depending on a number of factors.

May 20, 2015
aidsmap

In this video an international panel of experts speak on the future of PrEP. AVAC's Executive Director, Mitchell Warren, urges us to "begin to act on the evidence" and use PrEP more widely outside clinical trials to see a public health impact.

April 29, 2015
The Body

A formative study was conducted in Nigeria to obtain data on public opinions, interest and perceptions on appropriate target groups for PrEP access and the use of PrEP as an HIV-prevention tool. Results found that sero-discordant couples were an appropriate target for PrEP and that there exists a high public interest for PrEP as an HIV prevention tool. The study also noted that there could be potential stigma that associated with PrEP, since the same drugs are also used to treat people living with HIV.

April 20, 2015
BMC Public Health

During a Q&A session for Gay Times Magazine, three main political party leaders of the UK all praised PrEP as an intervention tool.

April 20, 2015
Pink News

A commentary from the leadership of the International AIDS Society on the urgency and relevance of implementing daily oral PrEP as an HIV prevention option for all people at risk of HIV. PrEP isn’t a magic bullet or a strategy that will be everything for everyone, but it’s a key choice to have at the right place at the right time for people in need.

April 17, 2015
The Lancet

Would sex workers take a single pill daily if it prevented HIV infection? Researchers at South Africa's Wits Reproductive Health and HIV Institute are trying to find out.

April 10, 2015
Subscribe to RSS - PrEP